Evidence map›Paper›PMID 42523331›Full record

ArticlebioRxiv : the preprint server for biology2026

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes.

Anagha Deshpande, Cho-Ying Chiang, Marlenne Perales, Neha Niranjan, Neelam Sinha, Darren Finlay, Alexandra Stevens, Emily Zahn, Benjamin A Garcia, Irmela Jeremias and 12 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Anagha DeshpandeSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Cho-Ying ChiangSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Marlenne PeralesSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Neha NiranjanSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Neelam SinhaSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Darren FinlaySanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Alexandra StevensBaylor College of Medicine, Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX 77030, USA.
Emily ZahnDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Irmela JeremiasGerman Cancer Consortium (DKTK), Heidelberg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Kristen Jensen-PergakesPfizer, Oncology Research & Development, San Diego, California.
Akshata UdyavarPfizer, Oncology Research & Development, San Diego, California.
Amy CarrPfizer, Oncology Research & Development, San Diego, California.
Andrew R NagerPfizer, Oncology Research & Development, San Diego, California.
Yanling YangPfizer, Oncology Research & Development, San Diego, California.
Rabi MuradSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Courtney JonesDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Shawn O'ConnellPfizer, Oncology Research & Development, San Diego, California.
Thomas PaulPfizer, Oncology Research & Development, San Diego, California.
Kristiina VuoriSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.
Aniruddha J DeshpandeSanford Burnham Prebys Medical Discovery Institute, NCI Designated Cancer Center, La Jolla, CA, USA.

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Molecular Pathogenesis of AF10-Rearranged LeukemiasR01CA262746 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Aniruddha J. Deshpande · 2022 to 2026
$2.2M
Therapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9M
Screening for Inhibitors of the Chromatin Reader SGF29R01CA301721 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Aniruddha J. Deshpande, Eduard A. Sergienko · 2025 to 2026
$1.5M
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA262746NCI NIH HHS R01 CA301721NCI NIH HHS R50 CA211404
6 · The paper itself

Abstract

Transcriptional condensates anchored by chromatin readers are increasingly recognized as organizing hubs for gene expression, but how their assembly and stability are regulated remains poorly understood. Here, we identify an acetylation-dependent feed-forward circuit that controls the integrity of the Super Elongation Complex (SEC), a key driver of transcriptional elongation. We show that the SAGA histone acetyltransferase catalytic subunits KAT2A/KAT2B license acetylation of both histone H3 lysine 9 (H3K9ac) and SEC components themselves, including ENL, AFF1, and AFF3. Loss of this dual acetylation activity, achieved via a cereblon-recruiting PROTAC (GSK983/GSK699), displaces the chromatin reader ENL from target loci, dissolves ENL-anchored transcriptional condensates, and disrupts SEC-dependent transcriptional output - linking histone and non-histone acetylation to the physical integrity of a core transcriptional machine. Using genome-scale dependency data, we show that the SAGA complex is a selective chromatin dependency in acute myeloid leukemia (AML) AML and hematological malignancies and disrupting this feed-forward transcriptional circuit in AML demonstrates subtype independent antileukemia effects. KAT2A/B degradation drives potent, broad-spectrum antileukemic activity across genetically diverse AML cell lines, primary patient samples, and an isogenic KMT2A-rearranged model bearing cooperating oncogenic mutations, with H3K9ac loss concentrated asymmetrically at core AML oncogene loci such as MYC, MYB, and the HOXA cluster. Together, these findings define an acetylation-dependent circuit governing SEC integrity and establish KAT2A/B degradation as a mechanism-based, pan-AML therapeutic strategy, with implications for transcriptional condensate regulation beyond leukemia.

Identifiers

PMID42523331
PMCPMC13404978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.